Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA-Reference-Cited by-同舟云学术

Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA

Published:2018 Issue:6 Volume:43 Page:369-375
ISSN:0388-1350
Container-title:The Journal of Toxicological Sciences
language:en
Short-container-title:J. Toxicol. Sci.

Author:

Murayama Norie¹,Suemizu Hiroshi²,Uehara Shotaro²,Kusama Takashi¹,Mitsui Marina¹,Kamiya Yusuke¹,Shimizu Makiko¹,Guengerich F. Peter³,Yamazaki Hiroshi¹

Affiliation:

1. Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University

2. Central Institute for Experimental Animals

3. Department of Biochemistry, Vanderbilt University School of Medicine, USA

Publisher

Japanese Society of Toxicology

Subject

Toxicology

Link

https://www.jstage.jst.go.jp/article/jts/43/6/43_369/_pdf

Reference23 articles.

1. Chanan-Khan, A.A., Lonial, S., Weber, D., Borrello, I., Foà, R., Hellmann, A., Dimopoulos, M., Swern, A.S. and Knight, R. (2012): Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. Int. J. Hematol., 96, 254-262.

2. Chen, N., Kasserra, C., Reyes, J., Liu, L. and Lau, H. (2012a): Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity. Cancer Chemother. Pharmacol., 70, 717-725.

3. Chen, N., Lau, H., Kong, L., Kumar, G., Zeldis, J.B., Knight, R. and Laskin, O.L. (2007): Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J. Clin. Pharmacol., 47, 1466-1475.

4. Chen, N., Wen, L., Lau, H., Surapaneni, S. and Kumar, G. (2012b): Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother. Pharmacol., 69, 789-797.

5. Chen, N., Zhou, S. and Palmisano, M. (2017): Clinical pharmacokinetics and pharmacodynamics of lenalidomide. Clin. Pharmacokinet., 56, 139-152.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanocomposite hydrogel to deliver the immunomodulator lenalidomide and anti-inflammatory hesperidin locally to joints affected by rheumatoid arthritis;Chemical Engineering Journal;2023-11

2. Centralized data sources and QSAR methods for the prediction of idiosyncratic adverse drug reaction;QSAR in Safety Evaluation and Risk Assessment;2023

3. Species Specificity and Selection of Models for Drug Oxidations Mediated by Polymorphic Human Enzymes;Drug Metabolism and Disposition;2022-06-30

4. Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies;Annals of Hematology;2022-06-22

5. Structure-Activity Relationship (SAR) Model for Predicting Teratogenic Risk of Antiseizure Medications in Pregnancy by Using Support Vector Machine;Frontiers in Pharmacology;2022-02-25